Mark Latina, MD
Ophthalmology · Reading, MANPI 1801886346
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $222,257 of the $279,025 with a category attached, or 79.7%. 32 manufacturers reported payments, led by AbbVie at 52.9% of the total. 2025 is the largest year on record at $73,910, 3.6 times the $20,295 reported in 2019. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 943 payments — averaging $295.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$148K
- Sight Sciences, Inc.$58K
- Alcon$43K
- Aerie Pharmaceuticals, Inc.$24K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$609
- Tarsus Pharmaceuticals, Inc.$600
- plus $6K from 26 others
Across 31 payments — averaging $584.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$18K
What the payments were for
- Consulting fees$8,9003%
- Speaking & faculty fees$222,25780%
- Travel & lodging$22,9418%
- Food & beverage$24,8439%
- Education$390%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 421 | $147,598 |
| Sight Sciences, Inc. | 82 | $58,334 |
| Alcon | 129 | $42,562 |
| Aerie Pharmaceuticals, Inc. | 54 | $23,640 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 38 | $609 |
| Tarsus Pharmaceuticals, Inc. | 13 | $600 |
| Glaukos Corporation | 8 | $598 |
| Amgen(2 entities) | 24 | $589 |
| Sun Pharmaceutical Industries Inc. | 20 | $574 |
| Iridex Corporation | 4 | $530 |
| Bausch & Lomb Americas Inc. | 32 | $505 |
| Mallinckrodt Hospital Products Inc. | 16 | $469 |
| Dompe US, Inc. | 10 | $416 |
| Thea Pharma Inc. | 28 | $360 |
| Oyster Point Pharma, Inc. | 8 | $326 |
| Novartis | 11 | $194 |
| Kala Pharmaceuticals, Inc. | 16 | $181 |
| Lumibird Medical Inc. | 1 | $154 |
| Biotissue Holdings Inc. | 8 | $154 |
| NEW World Medical,inc. | 4 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $120 |
| ANI Pharmaceuticals, Inc. | 4 | $102 |
| Visionix USA, Inc | 1 | $95 |
| Omeros Corporation | 2 | $27 |
| Akorn, Inc. | 1 | $25 |
| Rxsight Inc | 1 | $23 |
| Eyepoint US, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $22 |
| Alimera Sciences, Inc. | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Rayner Intraocular Lenses Limited | 1 | $17 |
| Merz North America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$108,817
- Rocklatan$62,575
- Rhopressa$58,496
- OMNI(R) SURGICAL SYSTEM (US)$54,437
- XEN GLAUCOMA TREATMENT SYSTEM$27,790
- SION SURGICAL INSTRUMENT$8,687
- LUMIGAN$4,351
- OMNI$3,112
- SIMBRINZA$1,500
- COMBIGAN$1,200
- XDEMVY$255
- Hydrus Microstent$177
- AcrySof IQ VIVITY$137
- iStent inject W$127
- EYLEA HD$120
- TEPEZZA$108
- Oxervate$107
- TYRVAYA$106
- EYSUVIS$105
- ACTHAR$100
How this compares
$279,025 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 57 | $75,840 |
| LumiganBimatoprost | 136 | $69,510 |
| CombiganBrimonidine Tartrate/Timolol | 108 | $47,617 |
| RhopressaNetarsudil Mesylate | 79 | $41,728 |
| Alphagan PBrimonidine Tartrate | 80 | $40,532 |
| Brimonidine Tartrate | 304 | $39,431 |
| Bromfenac Sodium | 155 | $36,219 |
| Brinzolamide | 211 | $35,878 |
| MieboPerfluorohexyloctane/Pf | 37 | $32,062 |
| ProlensaBromfenac Sodium | 59 | $22,377 |
| AzoptBrinzolamide | 38 | $17,500 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $13,377 |
| Prednisolone Acetate | 351 | $12,673 |
| Pilocarpine Hcl | 223 | $12,462 |
| RocklatanNetarsudil Mesylat/Latanoprost | 34 | $11,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $147,598 | $233,498381 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $23,640 | $53,168113 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $505 | $36,95748 claims |
| AlconAzopt, Simbrinza | $42,562 | $30,87777 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $609 | $25,58974 claims |
| Thea Pharma Inc.Iyuzeh | $360 | $5,30915 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $181 | $4,22214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Reading
- John NolanReading$18K
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Jeremy KievalLexington$232K
- Mina FarahaniBoston$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.